New Zealand - English - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine - solution for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine excipient: water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

sandoz new zealand limited - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml of vinorelbine excipient: water for injection - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first-line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

New Zealand - English - Medsafe (Medicines Safety Authority)

new zealand medical & scientific ltd - vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine - solution for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to 10 mg/ml vinorelbine excipient: water for injection

New Zealand - English - Medsafe (Medicines Safety Authority)

pfizer new zealand limited - vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85mg equivalent to to 10 mg vinorelbine excipient: nitrogen water for injection - dbl™ vinorelbine injection concentrate is indicated as a single agent or in combination for 1. the treatment of non small cell lung cancer (nsclc), and 2. the second line treatment of advanced breast cancer.

New Zealand - English - Medsafe (Medicines Safety Authority)

rex medical ltd - vinorelbine tartrate 13.85 mg/ml equivalent to vinorelbine 10 mg/ml - concentrate for injection - 10 mg/ml - active: vinorelbine tartrate 13.85 mg/ml equivalent to vinorelbine 10 mg/ml excipient: nitrogen sodium hydroxide water for injection - second-line treatment of advanced breast cancer, as a single agent or in combination.

Singapore - English - HSA (Health Sciences Authority)

mylan pharmaceuticals pte. ltd. - vinorelbine tartrate 13.85 mg/ml equivalent to vinorelbine - injection, solution, concentrate - 10 mg/ml - vinorelbine tartrate 13.85 mg/ml equivalent to vinorelbine 10 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

generics (uk) limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml - vinca alkaloids and analogues

Ireland - English - HPRA (Health Products Regulatory Authority)

strides arcolab international limited - vinorelbine tartrate - concentrate for soln for inf - 10 mg/ml

Ireland - English - HPRA (Health Products Regulatory Authority)

actavis group ptc ehf - vinorelbine ditartrate - concentrate for soln for inf - 10 mg/ml

Australia - English - Department of Health (Therapeutic Goods Administration)

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.